Newsfeeds Archive - Page 2 of 3

2 minute read

New Clinical MDMA And Psilocybin Batches Head To Flourishing Psychedelics Market

April 25, 1:30 PM

Psychedelics developer PharmAla Biotech continues to provide its Good Manufacturing Practices (GMP)-compliant psychedelics to Australian-based businesses developing clinical trials and, soon, actual treatments with the substances.

IXHL

4 minute read

Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More

By Lara Goldstein

March 20, 5:11 PM

Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered

BRAXF

2 minute read

Two Major Psychedelics Companies Take Novel Chemical Entity Patent Battle To Federal Court

By Lara Goldstein

March 14, 2:24 PM

Clinical-stage biopharma company Reunion Neuroscience Inc. (NASDAQ: REUN) filed a lawsuit against drug discovery business Mindset Pharma Inc. (OTCQB: MSSTF) in the District Court of New Jersey.

MSSTF

5 minute read

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More

By Lara Goldstein

March 13, 5:13 PM

Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial

ATAI

2 minute read

Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded

By Lara Goldstein

February 3, 5:38 PM

Silo Pharma Sees Growth In IP With New US Patent For Novel Ketamine Method On Stress-Induced Affective Disorders

MSSTF

4 minute read

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More

By Lara Goldstein

January 25, 1:02 PM

Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?

CLABF

2 minute read

Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News

By Lara Goldstein

January 21, 3:52 PM

Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”

MSSTF